Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphoglucomutase-like protein 5 (PGM5), also referred to as aciculin, is a protein found primarily in muscle tissue where it functions as a dynamic structural multi-adaptor involved in myofibril organization and maintenance[2]. PGM5 interacts with key muscle proteins such as Filamin C (FLNc) and Xin actin-binding proteins, localizing to critical muscle cell structures including intercalated discs, myotendinous junctions, and Z-discs[2]. Unlike its close homolog phosphoglucomutase 1 (PGM1), PGM5 does not exhibit enzymatic activity for phosphoglucomutase reactions, likely due to differences in active-site loops, but retains high structural similarity within the alpha-D-phosphohexomutase family[1]. Functional studies demonstrate that PGM5 is crucial for muscle development and remodeling, with loss-of-function experiments leading to severe myofibril defects in cell and animal models[2]. Currently, PGM5 is not recognized as a therapeutic target, and there are no known drugs targeting this protein[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphoglucomutase-like protein 5 (PGM5).